| scholarly article | Q13442814 |
| P50 | author | Jasvinder Singh | Q50285669 |
| P2093 | author name string | L Chen | |
| Kevin L Winthrop | |||
| S Yang | |||
| G W Cannon | |||
| T R Mikuls | |||
| A Kamauu | |||
| J W Baddley | |||
| K G Saag | |||
| E Delzell | |||
| J R Curtis | |||
| M J Burton | |||
| M M Safford | |||
| K Alexander | |||
| P Napalkov | |||
| N M Patkar | |||
| S DuVall | |||
| P2860 | cites work | Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score | Q24817087 |
| Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. | Q31123685 | ||
| A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries | Q34216770 | ||
| Measurement in Veterans Affairs Health Services Research: veterans as a special population | Q34337728 | ||
| Associations of disease activity and treatments with mortality in men with rheumatoid arthritis: results from the VARA registry | Q35025293 | ||
| The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents | Q35082559 | ||
| Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? | Q35249608 | ||
| Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics? | Q35899264 | ||
| Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists | Q36013844 | ||
| Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases | Q36191250 | ||
| Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study | Q36610390 | ||
| Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register | Q36679750 | ||
| Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate | Q36930704 | ||
| Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients. | Q37286386 | ||
| Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis | Q38085877 | ||
| Predictors of infection in rheumatoid arthritis | Q40629895 | ||
| Veteran's affairs hospital discharge databases coded serious bacterial infections accurately | Q43879445 | ||
| Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. | Q44337775 | ||
| Infections in patients with rheumatoid arthritis treated with biologic agents | Q44952372 | ||
| Accuracy of Veterans Administration databases for a diagnosis of rheumatoid arthritis | Q45333297 | ||
| Influence of serotonergic 5-HT2C receptor antagonist mesulergine in the reversal of memory deficits induced by mCPP. | Q50968752 | ||
| High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. | Q51607073 | ||
| Evaluating Medication Effects Outside of Clinical Trials: New-User Designs | Q52956338 | ||
| Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register | Q56969723 | ||
| Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor α antagonists and disease-modifying antirheumatic drugs | Q58974278 | ||
| Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists | Q58974447 | ||
| Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis | Q80388423 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| veteran | Q193891 | ||
| hospitalization | Q3140971 | ||
| P304 | page(s) | 990-997 | |
| P577 | publication date | 2014-07-01 | |
| P1433 | published in | Arthritis Care and Research | Q15754720 |
| P1476 | title | Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis | |
| P478 | volume | 66 |
| Q91600659 | A Veteran With Fibromyalgia Presenting With Dyspnea |
| Q27028059 | Actinomyces and related organisms in human infections |
| Q40598586 | Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare |
| Q33778719 | Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan. |
| Q33841390 | Dose relationship between oral glucocorticoids and tumor necrosis factor inhibitors and the risk of hospitalized infectious events among patients with rheumatoid arthritis |
| Q52642347 | Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study. |
| Q58780594 | Frequency of Hospitalized Infections Is Reduced in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs after 2010 |
| Q93333689 | Gold Nanoparticles with Antibiotic-Metallopolymers toward Broad-Spectrum Antibacterial Effects |
| Q47625115 | Impact of Sustained Remission on the Risk of Serious Infection in Patients With Rheumatoid Arthritis |
| Q30245503 | Infections With Biologics in Rheumatoid Arthritis and Related Conditions: a Scoping Review of Serious or Hospitalized Infections in Observational Studies |
| Q38673326 | Not all TNF inhibitors in rheumatoid arthritis are created equal: important clinical differences |
| Q38944886 | Phenome-Wide Association Study of Rheumatoid Arthritis Subgroups Identifies Association Between Seronegative Disease and Fibromyalgia |
| Q88774468 | Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials |
| Q41928628 | Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE. |
| Q40097140 | Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab. |
| Q90665225 | Risk of Hospitalized Infection and Initiation of Abatacept Versus Tumor Necrosis Factor Inhibitors Among Patients With Rheumatoid Arthritis: A Propensity Score-Matched Cohort Study |
| Q38827889 | Safety and Efficacy of Biological Disease-Modifying Antirheumatic Drugs in Older Rheumatoid Arthritis Patients: Staying the Distance |
| Q64993375 | Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study. |
| Q45120346 | Secretory expression of a bispecific antibody targeting tumor necrosis factor and ED-B fibronectin in Pichia pastoris and its functional analysis |
| Q38983259 | Severe infection in patients with rheumatoid arthritis taking anakinra, rituximab, or abatacept: a systematic review of observational studies |
| Q89210678 | Sustained stimulation of β2- and β3-adrenergic receptors leads to persistent functional pain and neuroinflammation |
| Q38812233 | Systematic review of the efficacy and safety of biological therapy for inflammatory conditions in HIV-infected individuals |
| Q38755133 | The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis |
| Q39192359 | The use of biologics in pregnant patients with rheumatic disease |
| Q48825054 | Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis |
| Q50154733 | Treatment of rheumatoid arthritis with biologic agents lowers the risk of incident chronic kidney disease |
| Q36182373 | Use of corticosteroids in patients with rheumatoid arthritis treated with infliximab: treatment implications based on a real-world Canadian population |
| Q38285275 | Vaccination of patients with autoimmune inflammatory rheumatic diseases |
| Q28074148 | What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis? |
Search more.